Press Releases MiNK Therapeutics, Inc.

Equities

INKT

US6036931029

Delayed Nasdaq Other stock markets 08:50:51 14/05/2024 pm IST			5-day change	1st Jan Change
1.06 ^USD	+8.19%		+13.97%	-0.93%

13/05	Wall Street Set to Open Higher Monday as Investors Look Toward Key Inflation Figures	MT
13/05	MiNK Therapeutics, Inc. announced that it expects to receive $5.8 million in funding	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MiNK Reports First Quarter 2024 Results	05:01pm	GL
MiNK Reports First Quarter 2024 Results	05:01pm	AQ
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer	13/05	GL
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer	13/05	AQ
MiNK to Provide Corporate Update and First Quarter 2024 Financial Report	30/04	GL
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR	08/04	GL
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR	08/04	AQ
MiNK Reports Fourth Quarter and Year-End 2023 Results	21/03	GL
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report	07/03	GL
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report	07/03	AQ
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024	06/03	GL
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024	06/03	AQ
First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab	14/02	GL
MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications	06/02	GL
MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications	06/02	AQ
MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene	30/01	GL
MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene	30/01	AQ
ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development	20/12	GL
MiNK Therapeutics Reports Third Quarter 2023 Results	09/11	GL
MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023	03/11	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases MiNK Therapeutics, Inc.

Equities

INKT

US6036931029

Press Releases

Filters